4-(4-nitrophenyl)butylamine | 80258-63-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-nitrophenyl)butylamine
• 英文别名: 4-(4-Nitrophenyl)butan-1-amine
• CAS: 80258-63-5
• 化学式: C₁₀H₁₄N₂O₂
• mdl: MFCD12190415
• 分子量: 194.233
• InChiKey: QPHLFSGMBIJFRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-nitrophenyl)butylamine 在 盐酸 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 5.0h， 生成 6-Fluoro-8-{2-[4-(4-nitro-phenyl)-butylamino]-ethoxy}-chroman-4-one
  参考文献：
  名称：

  Synthesis and Pharmacological Characterization of Novel 6-Fluorochroman Derivatives as Potential 5-HT_1A Receptor Antagonists

  摘要：

  A series of novel 6-fluorochroman derivatives was prepared and evaluated as antagonists for the 5-HT1A receptor. N-2- [[(6-Fluorochroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamine (3; J. Med. Chem. 1997, 40, 1252-1257) was chosen as a lead, and structural modifications were done on the aliphatic portion of the chroman ring, the tether linking the middle amine and the terminal aromatic ring, the aromatic ring, and lastly the amine. Radioligand binding assays proved that the majority of the novel compounds behaved as good to excellent ligands at the 5-HT1A receptor, some of which were selective with respect to alpha(1)-adrenergic and D-2-dopaminergic receptors. The antagonist activity of the compounds was assessed in the forskolin-stimulated adenylate cyclase assays in CHO cells expressing the human 5-HT1A receptors. Among the modifications attempted, introduction of an oxo or an optically active hydroxy moiety at the chroman C-4 position was effective in ameliorating the receptor selectivity. Six analogues were selected through the in vitro screeds and further evaluated for their in vivo activities. A 4-oxochroman derivative (31n), having a terminal 1,3-benzodioxole ring, demonstrated antagonist activities toward 8-OH-DPAT-induced behavioral and electrophysiological responses in rats.

  DOI：

  10.1021/jm9707840
• 作为产物：
  描述：

  4-(4-硝基苯)丁酸 在 三(2-氯乙基)胺 作用下， 以 氯仿 为溶剂， 反应 4.0h， 生成 4-(4-nitrophenyl)butylamine
  参考文献：
  名称：

  潜在的抗肿瘤药。36.一般9-苯胺基oa啶类抗肿瘤剂的实验抗肿瘤活性，毒性和结构之间的定量关系。

  摘要：

  已针对9类苯胺基between啶类化合物中的509种肿瘤活性成员，在抗白血病（L1210）活性与药物理化性质之间建立了定量关系（QSAR）。此类药物之一是临床药物m-AMSA（NSC 249992）。试剂疏水性已证明对体内效力有显着但非主要的影响。取代基的电子性质被证明是重要的，但是对药物效力的最显着影响是通过位于9-苯胺基cr啶骨架上不同位置的基团的空间影响显示出来的。这些结果与这些化合物发挥作用的重要生理步骤完全一致，它们是通过在碱基对之间插入idine啶发色团并在小沟中放置苯胺基而将它们与双链DNA结合的，如前所述。还推导了9-苯胺基cr啶的643种衍生物的急性毒性方程。该方程采用与模拟抗白血病药效价相似的形式，强调了抗肿瘤药的药效和急性毒性之间通常相当紧密的关系。这项研究证明了QSAR技术的强大功能，可以构建大量的生物学数据，并允许从中提取有用的信息，这取决于有关化合物的可能作用部

  DOI：

  10.1021/jm00345a015

文献信息

• Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents
  作者：William A. Denny、Bruce F. Cain、Graham J. Atwell、Corwin Hansch、Augustine Panthananickal、A. Leo

  DOI：10.1021/jm00345a015

  日期：1982.3

  relationships (QSAR) have been derived between antileukemic (L1210) activity and agent physicochemical properties for 509 tumor-active members of the general class of 9-anilinoacridines. One member of this class is the clinical agent m-AMSA (NSC 249992). Agent hydrophobicity proved a significant but not a dominant influence on in vivo potency. The electronic properties of substituent groups proved important

  已针对9类苯胺基between啶类化合物中的509种肿瘤活性成员，在抗白血病（L1210）活性与药物理化性质之间建立了定量关系（QSAR）。此类药物之一是临床药物m-AMSA（NSC 249992）。试剂疏水性已证明对体内效力有显着但非主要的影响。取代基的电子性质被证明是重要的，但是对药物效力的最显着影响是通过位于9-苯胺基cr啶骨架上不同位置的基团的空间影响显示出来的。这些结果与这些化合物发挥作用的重要生理步骤完全一致，它们是通过在碱基对之间插入idine啶发色团并在小沟中放置苯胺基而将它们与双链DNA结合的，如前所述。还推导了9-苯胺基cr啶的643种衍生物的急性毒性方程。该方程采用与模拟抗白血病药效价相似的形式，强调了抗肿瘤药的药效和急性毒性之间通常相当紧密的关系。这项研究证明了QSAR技术的强大功能，可以构建大量的生物学数据，并允许从中提取有用的信息，这取决于有关化合物的可能作用部
• Ruthenium-Catalyzed C–H Hydroxylation in Aqueous Acid Enables Selective Functionalization of Amine Derivatives
  作者：James B. C. Mack、John D. Gipson、J. Du Bois、Matthew S. Sigman

  DOI：10.1021/jacs.7b05469

  日期：2017.7.19

  catalytic protocol for sp3 C-H hydroxylation is described. Reactions are performed in aqueous acid using a bis(bipyridine)Ru catalyst to enable oxidation of substrates possessing basic amine functional groups. Tertiary and benzylic C-H hydroxylation is strongly favored over N-oxidation for numerous amine derivatives. With terpene-derived substrates, similar trends in reactivity toward tertiary and benzylic

  描述了用于 sp3 CH 羟基化的新催化协议的识别、优化和评估。反应在酸水溶液中使用双（联吡啶）Ru 催化剂进行，以氧化具有碱性胺官​​能团的底物。对于许多胺衍生物，叔和苄基 CH 羟基化比 N-氧化更受青睐。对于萜烯衍生的底物，观察到对叔和苄基 CH 键的反应性的类似趋势。尽管反应介质具有电离强度，但手性三级中心的羟基化是对映特异性的。初步动力学实验显示异构顺式和反式 Ru 催化剂之间的反应性存在显着差异，表明该催化剂在反应条件下构型稳定。
• NOVEL DIAMINE, POLYAMIC ACID, AND POLYIMIDE
  申请人：NISSAN CHEMICAL INDUSTRIES. LTD.

  公开号：US20160264520A1

  公开（公告）日：2016-09-15

  To provide a novel diamine, and a polyimide precursor and a polyimide using it. A diamine represented by the formula (1): wherein each of X 1 and X 5 which are independent of each other, is a single bond or the like; each of X 2 and X 4 which are independent of each other, is —CH 2 — or the like; X 3 is a C 1-6 alkylene or the like; each of Y 1 and Y 2 which are independent of each other, is a single bond or the like; R is a C 1-20 linear, branched or cyclic hydrocarbon group; and a is 0 or 1).

  提供一种新颖的二胺，以及使用它的聚酰亚胺前体和聚酰亚胺。一种由式（1）表示的二胺：其中X1和X5中的每一个独立的，是单键或类似物；X2和X4中的每一个独立的，是—CH2—或类似物；X3是C1-6烷基或类似物；Y1和Y2中的每一个独立的，是单键或类似物；R是C1-20线性、支链或环烃基；a为0或1。
• [EN] BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS<br/>[FR] DÉRIVÉS DE BENZOXAZOLONE EN TANT QU'INHIBITEURS DE LA CÉRAMIDASE ACIDE, ET LEUR UTILISATION COMME MÉDICAMENTS
  申请人：FOND ISTITUTO ITALIANO DI TECNOLOGIA

  公开号：WO2015173168A1

  公开（公告）日：2015-11-19

  The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides benzoxazolone derivatives for use as a medicament in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.

  本发明涉及苯并噁唑酮衍生物作为酸酶抑制剂，含有这些抑制剂的药物组合物以及用于抑制酸酶治疗临床相关的调节神经酰胺水平的疾病的方法。该发明还提供苯并噁唑酮衍生物作为药物在治疗癌症、炎症、疼痛、炎症性疼痛或肺部疾病中的用途。
• Synthesis of Potent Non-imidazole Histamine H3-Receptor Antagonists
  作者：C. Robin Ganellin、Fabien Leurquin、Antonia Piripitsi、Jean-Michel Arrang、Monique Garbarg、Xavier Ligneau、Walter Schunack、Jean-Charles Schwartz

  DOI：10.1002/(sici)1521-4184(199812)331:12<395::aid-ardp395>3.0.co;2-7

  日期：1998.12

  Histamine has been converted into a non‐imidazole H3‐receptor histamine antagonist by addition of a 4‐phenylbutyl group at the Nα‐position followed by removal of the imidazole ring. The resulting compound, N‐ethyl‐N‐(4‐phenylbutyl)amine, remarkably has a Ki = 1.3 μM as an H3 antagonist. Using this as a lead compound, a novel series of homologous O and S isosteric tertiary amines was synthesised and

  通过在 Nα-位添加 4-苯基丁基，然后去除咪唑环，组胺已转化为非-咪唑 H3-受体组胺拮抗剂。所得化合物 N-乙基-N-（4-苯基丁基）胺作为 H3 拮抗剂具有显着的 Ki = 1.3 μM。使用它作为先导化合物，合成了一系列新的同源 O 和 S 等排叔胺，结构-活性研究提供了 N-（5-苯氧基戊基）吡咯烷（Ki = 0.18 ± 0.10 μM，用于 [3H] 组胺从大鼠中释放大脑皮层突触体），更重要的是，它在体内是活跃的。将 NO2 取代到苯氧基的对位得到 N-(5-p-硝基苯氧基戊基)吡咯烷，UCL 1972 (Ki = 39 ± 11 nM)，ED50 = 1.1 ± 0.6 mg / kg per os in 脑远程小鼠甲基组胺水平。